Clinical validation of a Unani Pharmacopeial formulation Habb-e-Sadr in Zeeq un Nafas(Bronchial Asthma) - NI

Central Council for Research in Unani Medicine CCRUM New Delhi0 sites0 target enrollmentStarted: TBDLast updated: July 22, 2024

Trial Snapshot

No summary available.

•1. Males and females of 18-65 years.
•2. Patients of Bronchial Asthma for at least 3 months presenting with at least one of the following symptoms:
•Shortness of breath
•Chest tightness and cough that vary over time
•and in intensity,
•Expiratory airflow limitation as suggested by a
•decreased FEV1
•3. Objective evidence for reversible airway obstruction (=12% and =200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment.
•4. Patients with Asthma Control Questionnaire Score more than 1.5

•1. FEV1/FVC ratio less than 50%.
•2. Pregnant and lactating mother
•3. Patient with other Respiratory Tract Infections, tuberculosis and malignancy.
•4. Patient of Presence of chronic cough with expectoration for 2-3 months in each of 2 successive years.
•5. Patient with co-morbidities, Diabetes Mellitus, Hepatic and Renal Insufficiency.
•6. Patients with Tobacco Smoking.
•7. Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.

Sponsor

Central Council for Research in Unani Medicine CCRUM New Delhi